

Special Issue

Molecular Mechanisms and Treatment of Thymic Epithelial Tumors

Message from the Guest Editors

Currently, early-stage thymic epithelial tumors are treated with surgical resection. For patients with advanced-stage or incomplete resected tumors, there is a necessity for adjuvant therapy, now consisting of platinum-based chemotherapy. The difficulties in TET treatment derive from their still largely unknown biology and pathogenetic mechanisms, and from the rarity of expert centers and lack of standardized treatments. A framework of expert multidisciplinary teams and of international networks is necessary in order to progress in our understanding and better deal with these rare tumors. We hereby invite contributions to this Special Issue of *Biomedicines* describing novel molecular alterations underlying the pathobiology of TETs, possibly influencing epithelial cell growth and survival. In addition, manuscripts discussing developments in diagnostics or therapeutics for TET are also encouraged. We invite researchers and clinicians to submit original research articles and comprehensive review articles on the topic highlighted in this Special Issue of *Biomedicines*.

Guest Editors

Prof. Dr. Georgia Levidou

Department of Pathology, Paracelsus Medical University, 90419 Nuremberg, Germany

Prof. Dr. Stamatios E. Theocharis

First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Goudi, Athens, Greece

Deadline for manuscript submissions

closed (31 December 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/154250

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).